Dipeptidyl‐peptidase IV inhibitors ( DPP4i )‐associated bullous pemphigoid: Estimating the clinical profile and exploring intraclass differences
Author:
Affiliation:
1. Clalit Health Services Haifa Israel
2. Lübeck Institute of Experimental, Dermatology, University of Lübeck, Lübeck Germany
3. Azrieli Faculty of Medicine, Bar‐Ilan University Safed Israel
Publisher
Wiley
Subject
Dermatology,General Medicine
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/dth.13790
Reference26 articles.
1. Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance Database
2. Dipeptidyl peptidase-IV inhibitors induced bullous pemphigoid: a case report and analysis of cases reported in the European pharmacovigilance database
3. Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: Retrospective multicenter case-control study from France and Switzerland
4. Vildagliptin Significantly Increases the Risk of Bullous Pemphigoid: A Finnish Nationwide Registry Study
5. Use of Dipeptidyl-Peptidase IV Inhibitors and Bullous Pemphigoid
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Two cases of linagliptin-associated bullous pemphigoid resulting in sepsis and endocarditis;BMJ Case Reports;2024-02
2. From Molecular Insights to Clinical Perspectives in Drug-Associated Bullous Pemphigoid;International Journal of Molecular Sciences;2023-11-26
3. Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: evaluation of clinical course and treatment response;Clinical and Experimental Dermatology;2023-04-26
4. Dipeptidyl peptidase‐4 inhibitors increase the risk of bullous pemphigoid in older patients with diabetes: A retrospective analysis using the Korean National Health Insurance Database;Journal of the European Academy of Dermatology and Venereology;2023-02-27
5. Enfermedades ampollosas autoinmunes en atención primaria;FMC - Formación Médica Continuada en Atención Primaria;2022-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3